© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Sydney Jennings
Articles
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
March 11, 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
March 11, 2025
AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.
Elizabeth Swanson, MD: When HSV Causes Big Dermatologic Problems
March 10, 2025
Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."
Recognizing Allergic Contact Dermatitis in Children: Expert Pearls at AAD 2025
March 10, 2025
JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.
The Complexities of Treating Rosacea, with Benjamin Ungar, MD
March 10, 2025
Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
March 09, 2025
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits
March 09, 2025
AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.
Benjmain Ungar, MD: Addressing the Immunological Causes of Seborrheic Dermatitis
March 09, 2025
Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
March 08, 2025
AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.
Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis
March 08, 2025
AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.